Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesPharmacy & Specialty DrugsAmeriHealth MCES Program Policy Update | OpenPayer
    Ask Trek AI about this page
    CurrentAmeriHealthPolicy N/A

    Most Cost-Effective Setting (MCES) Program Drug List

    Customize your policy alerts

    Sign up for all AmeriHealth policy alerts

    Know when AmeriHealth releases new policies or updates existing guidance.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    Defines the AmeriHealth Most Cost-Effective Setting Program listing medications for which the treatment setting must be approved as part of precertification; affects providers requesting medical-benefit administration of listed drugs for AmeriHealth members.

    Policy Summary
    PayerAmeriHealth
    PolicyMost Cost-Effective Setting (MCES) Program Drug List
    Policy CodePolicy N/A
    Change TypeImmunotherapy expansion added (May 1, 2026)
    Effective DateJan 1, 2012
    Next Review DateTBD
    Key ActionObtain AmeriHealth precertification approval of the treatment setting before scheduling medical-benefit administration of listed drugs.
    SourceLink
    POLICY UPDATE CHANGES

    An Immunotherapy MCES Expansion listing oncology immunotherapy agents and criteria for outpatient continuation was launched May 1, 2026.

    Multiple new drugs were added to the MCES Program with various 'Date Added' entries through 2026 (e.g., Avtozma, Bildyos, Bosaya, Enoby, Imaavy, Imuldosa, Qivigy, Starjemza).

    100+drugs listed under MCES (approx.)
    Jan 1, 2012

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    Program established / IVIG inclusion
    May 1, 2026Immunotherapy expansion effective
    Subject to changeList changeability

    Coverage Criteria & Immunotherapy Expansion

    MCES Program Coverage and Immunotherapy Expansion Exceptions

    Covered when ALL of the following are met

    MCES precertification requirement: AmeriHealth approval of the treatment setting has been obtained via precertification and the member meets the medical policy coverage criteria for the requested medication.

    Applies to drugs listed in the MCES Program and their generics/biosimilars; review is conducted as part of the precertification process.

    Immunotherapy outpatient continuance exceptions

    • Receiving combination therapy: Receiving a provider-administered combination chemotherapy at the same visit.
    • Age: Patient is less than 18 years of age.
    • Early dosing period: Within the first 3 doses of starting therapy.
    • Severe toxicity monitoring: Experiencing severe toxicity requiring continuous monitoring (e.g., myocarditis, pericarditis, arrhythmias, impaired ventricular function).

    The Immunotherapy MCES Expansion (effective May 1, 2026) allows certain oncology immunotherapy agents to remain administered in the outpatient setting only when specific continuation conditions are met. Members will continue to receive outpatient care if any of the following apply: receiving a provider‑administered combination chemotherapy at the same visit; the patient is less than 18 years of age; the treatment is within the first 3 doses of starting therapy; or the patient is experiencing severe toxicity requiring continuous monitoring (examples include myocarditis, pericarditis, arrhythmias, impaired ventricular function). These exceptions apply specifically to the immunotherapy agents added under the May 1, 2026 expansion.

    Coverage for medications listed in the MCES Program requires that AmeriHealth approval of the treatment setting be obtained through the precertification process and that the member meet the underlying medical policy coverage criteria for the requested drug. For the Immunotherapy MCES Expansion, precertification and documentation that medical‑policy criteria are met remain required; the expansion only permits outpatient continuation when the specified exceptions are present.

    Provider Requirements and Precertification

    Prior Authorization

    Treatment setting approval required

    AmeriHealth must approve the treatment setting for medications on the Most Cost-Effective Setting (MCES) Program drug list. This review is performed during the precertification process to confirm the member meets applicable medical policy coverage criteria and that the requested treatment setting is safe and cost‑effective.

    • MCES Program applies to the drugs listed on the MCES Program Drug List (see policy drug list).
    • All generics and biosimilars to a reference product on the MCES list are subject to precertification review.
    Note

    Biosimilar/generic precertification

    All generics and biosimilars of reference products included in the MCES Program are subject to the same precertification review as brand products to determine appropriate treatment setting and coverage under AmeriHealth medical policy.

    Key Definitions

    IVIG/SCIG class
    DefinitionIntravenous/subcutaneous immunoglobulin (IVIG/SCIG) class — immunoglobulin therapies included in the Most Cost-Effective Setting (MCES) Program.
    MCES inclusion effective dateJanuary 1, 2012 (IVIG/SCIG class added to MCES on this date).
    Scope noteSome IVIG/SCIG products approved by the FDA after January 1, 2012 are reflected with the January 1, 2012 date to indicate when program requirements went into effect for the class.
    Typical settings impactedOffice, infusion center, hospital outpatient, home — treatment setting approval required via precertification for listed products.
    Immunotherapy MCES Expansion
    DefinitionImmunotherapy MCES Expansion — addition of specified oncology immunotherapy agents to the MCES Program effective May 1, 2026.

    Approved Sites of Care

    Note

    Site-of-care approval (office | infusion center | hospital outpatient | home)

    AmeriHealth must approve the treatment setting (site of care) for listed MCES medications via the precertification process; the Immunotherapy MCES Expansion includes specific conditions under which members may continue care in the outpatient setting.

    • Approved settings include: office, infusion center, hospital outpatient, or home (approval obtained through precertification).
    • Immunotherapy outpatient continuation applies if patient is receiving a provider‑administered combo chemotherapy at the same visit; is <18 years old; is within the first 3 doses of therapy; or is experiencing severe toxicity requiring continuous monitoring.

    Step Therapy / Program Application

    Policy itemDetails
    Generics and biosimilarsAll generics and biosimilars to a reference product included in the MCES Program are subject to precertification review for the most cost‑effective setting.

    Biosimilar Handling

    Billing Rule

    Biosimilars and generics require precertification

    Reiterate: all generics and biosimilars to reference products in the MCES Program require precertification review to establish the most cost‑effective setting.

    Program Background

    The Most Cost‑Effective Setting (MCES) Program was established to manage the total cost of care by ensuring members meet medical policy coverage criteria and that the treatment setting for certain medical‑benefit drugs is safe and cost‑effective. AmeriHealth conducts this review as part of the precertification process and requires approval of the treatment setting for listed drugs (examples: office, infusion center, hospital outpatient, or home). The program originally included the IVIG/SCIG class beginning January 1, 2012 and was expanded on May 1, 2026 to include select oncology immunotherapy agents with defined outpatient continuation rules.

    Policy Summary
    PayerAmeriHealth
    PolicyMost Cost-Effective Setting (MCES) Program Drug List
    Policy CodePolicy N/A
    Change TypeImmunotherapy expansion added (May 1, 2026)
    Effective DateJan 1, 2012
    Next Review DateTBD
    Key ActionObtain AmeriHealth precertification approval of the treatment setting before scheduling medical-benefit administration of listed drugs.
    SourceLink
    On This Page
    Coverage Criteria & Immunotherapy ExpansionProvider Requirements and PrecertificationKey DefinitionsApproved Sites of CareStep Therapy / Program ApplicationBiosimilar HandlingProgram Background
    Documentation Required

    Precertification documentation

    Documentation submitted with the precertification request must demonstrate that the member meets the applicable medical policy coverage criteria and include information supporting that the requested treatment setting meets MCES program requirements (for example: clinical rationale for setting, prior treatments and responses, relevant labs/imaging, and any supporting specialty consult notes).

    • Include sufficient clinical records to show medical necessity and why the chosen setting is required.
    • Document prior authorization or precertification identifiers and clinician contact information.
    Denial Risk

    Precertification required

    Failure to obtain AmeriHealth approval of the treatment setting prior to administration may result in denial of coverage or payment. Providers should obtain precertification approval that specifically authorizes the treatment setting for the listed medication.

    • Do not assume site-of-care coverage without prior AmeriHealth approval.
    • Verify precertification decision includes approved setting before scheduling or administering therapy.
    Effective dateMay 1, 2026 (Immunotherapy MCES Expansion launched).
    Outpatient continuation exceptionsMembers may continue to receive care in the outpatient setting if ANY of the following apply: receiving a provider‑administered combination chemotherapy at the same visit; patient is less than 18 years of age; within the first 3 doses of starting therapy; experiencing severe toxicity requiring continuous monitoring (e.g., myocarditis, pericarditis, arrhythmias, impaired ventricular function).
    Example agents addedDarzalex/Faspro; Imfinzi; Jemperli; Keytruda/Qlex; Libtayo; Loqtorzi; Opdivo/Qvantig; Rybrevant/Faspro; Tecentriq/Hybreza; Zynyz (all Date Added = May 1, 2026).
    Program ruleAll generics and biosimilars to a reference product in this expansion are subject to precertification review for the most cost‑effective setting; list is subject to change.